Keyphrases
Kidney Transplant Recipients
100%
Kidney Transplantation
91%
Hemodialysis Patients
49%
Graft Survival
46%
Chronic Kidney Disease
37%
Hemodialysis
36%
Confidence Interval
35%
Acute Kidney Injury
34%
Systematic Meta-analysis
33%
Graft Loss
31%
Retrospective Cohort Study
25%
Transplantation
25%
Cardiovascular Morbidity
25%
Humoral Response
24%
Obesity
24%
Dialysis
24%
Multivariate Analysis
23%
SIADH
23%
Meta-analysis
23%
Cardiovascular Mortality
22%
Kidney Transplant
22%
BNT162b2 Vaccine
22%
Immunosuppression
22%
Estimated Glomerular Filtration Rate
22%
DNA Repair
22%
Glomerular Hyperfiltration
22%
Dialysis Patients
21%
Single Center
21%
Peripheral Blood Mononuclear Cells
17%
Immunosuppression Reduction
17%
Randomized Controlled Trial
17%
Hazard Ratio
17%
Anemia of Chronic Kidney Disease
16%
COVID-19
16%
Odds Ratio
16%
All-cause Mortality
15%
Third Dose
15%
Bacterial Infection
15%
Pretransplant
15%
Antibody Response
15%
Hemoglobin
15%
Patient Survival
15%
First Year
14%
Intravenous Iron
14%
Vaccine Dose
14%
Etiology
14%
BNT162b2
14%
Increased Mortality
14%
Chronic Kidney Disease Patients
13%
Major Adverse Cardiovascular Events
13%
Medicine and Dentistry
Kidney Graft
86%
Kidney Transplantation
76%
Hemodialysis
49%
Chronic Kidney Disease
44%
Acute Kidney Injury
35%
Graft Failure
31%
Immunosuppressive Treatment
28%
Infection
27%
Retrospective Cohort Study
24%
Iron
24%
Kidney Function
24%
Glomerular Filtration Rate
24%
Cardiovascular System
24%
Randomized Controlled Trial
23%
Supplementation
23%
Ultrafiltration
22%
Graft Survival
22%
Systematic Review
22%
Meta-Analysis
22%
Retrospective Study
21%
Anemia
21%
DNA Repair
16%
Multivariate Analysis
16%
Bacterial Infection
15%
Cardiovascular Disease
14%
Hazard Ratio
14%
Diabetes
13%
Cohort Analysis
13%
Nephropathy
13%
Cancer
12%
Peripheral Blood Mononuclear Cell
12%
Inappropriate Vasopressin Secretion
12%
Bloodstream Infection
11%
Humoral Immunity
11%
COVID-19 Vaccine
11%
Percutaneous Aortic Valve Replacement
11%
Odds Ratio
10%
Diabetes Mellitus
10%
All Cause Mortality
10%
Retransplantation
9%
Calcineurin Inhibitor
9%
Antibody Response
9%
End Stage Renal Disease
8%
Living Donors
8%
Univariate Analysis
8%
Immunosuppressive Drug
8%
Prevalence
8%
Proportional Hazards Model
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Angiotensin Receptor Antagonist
7%